FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely cardiology, and concerns the treatment of essential hypertension. For this purpose examine the changes of pro-and anti-inflammatory markers of blood: MCP-1, IP-10, vchSRB and IL-10 before treatment and 3 months after the start of treatment. When the MCP-1 indices change from 55.7±8.6 pg/ml to 45.2±7.4 pg/ml, IP-10 from 309.2±15.4 pg/ml to 321.6±19.1 pg/ml, vchSRB from 0.71 pg/ml to 0.63 pg/ml; and increasing the level of IL-10, antihypertensive therapy is assessed as effective.
EFFECT: method provides the possibility of an objective assessment of the effectiveness of antihypertensive therapy and its timely individual correction.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH STAGE II ESSENTIAL ARTERIAL HYPERTENSION WITHIN 12 MONTHS AFTER COVID-19 | 2021 |
|
RU2767624C1 |
| METHOD OF PREDICTING VASCULAR DISORDERS IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION | 2009 |
|
RU2428105C2 |
| METHOD OF PREDICTION OF ASPIRIN RESISTANCE | 2015 |
|
RU2602664C1 |
| METHOD FOR DETERMINING DIAGNOSTIC CRITERION OF VASCULAR WALL STIFFNESS IN PATIENTS SUFFERING ARTERIAL HYPERTENSION ACCOMPANIED BY ABDOMINAL OBESITY | 2014 |
|
RU2567606C1 |
| METHOD OF ASSESSING AGE-RELATED CHANGES OF HUMAN CARDIOVASCULAR SYSTEM | 2012 |
|
RU2485886C1 |
| PREDICTION METHOD OF ARTERIAL HYPERTENSION COMORBIDE FORM AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE DEVELOPMENT | 2016 |
|
RU2620566C1 |
| METHOD OF EARLY DIAGNOSTICS OF ARTERY REMODELLING IN CASE OF ARTERIAL HYPERTENSION FORMATION | 2009 |
|
RU2414849C1 |
| METHOD FOR TREATING ARTERIAL HYPERTENSION | 2006 |
|
RU2310457C1 |
| METHOD FOR RESTENOSIS DEVELOPMENT PREDICTION IN PATIENTS WITH STABLE EXERTIONAL ANGINA FOLLOWING CORONARY STENTING | 2020 |
|
RU2724279C1 |
| METHOD OF THE EARLY POSTOPERATIVE PERIOD COURSE ESTIMATION IN PATIENTS OPERATED FOR CHRONIC RHEUMATIC HEART DISEASE | 2017 |
|
RU2642600C1 |
